# US 2016/0258969 A1 · Methods and Systems for Measuring Serotonin in a Sample

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0258969 A1
- Document ID: US20160258969A1
- Status: Published application
- Kind: A1
- Application number: 15/059,957
- Filed: 2016-03-03
- Published: 2016-09-08
- Earliest claimed: 2015-03-03
- Assignees: Laboratory Corporation of America Holdings
- Applicants: Laboratory Corporation of America Holdings
- Inventors: Matthew Lee Francis Crawford; Yvonne Zamorano Wright; Russell Philip Grant
- Web page: https://patentgrep.com/patent/US20160258969A1

## CPC

- G01N 33/942: {Serotonin, i.e. 5-hydroxy-tryptamine}
- G01N 33/49: Blood {(chemical methods for determining blood cell populations G01N33/5094; chemical analysis of blood groups or blood types G01N33/80)}
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G01N 2030/8813: {biological materials}
- G01N 2458/15: Non-radioactive isotope labels, e.g. for detection by mass spectrometry
- G01N 2800/222: Platelet disorders
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed are methods and systems for measuring serotonin in a sample using liquid chromatography and mass spectrometry.

## Claims

### Claim 1

A method for determining the presence or amount of released serotonin in a sample, the method comprising:
providing a sample comprising a biological sample, donor platelets, and heparin;
incubating the sample for a period of time to release serotonin from the donor platelets;
chromatographically separating serotonin from other components in the incubated sample using liquid chromatography; and
analyzing the chromatographically separated serotonin by mass spectrometry to determine the presence or amount of released serotonin in the sample.

### Claim 2 (depends on 1)

The method of claim 1, wherein the biological sample is a serum sample or a plasma sample.

### Claim 3 (depends on 1)

The method of claim 1, wherein the biological sample is obtained from a heparin-treated subject.

### Claim 4 (depends on 1)

The method of claim 1, wherein the biological sample is obtained from a subject suspected of having heparin-induced thrombocytopenia.

### Claim 5 (depends on 1)

The method of claim 1, wherein the donor platelets are obtained from at least one presumed healthy subject.

### Claim 6 (depends on 1)

The method of claim 1, wherein the donor platelets in the sample are washed and partially purified.

### Claim 7 (depends on 1)

The method of claim 1, wherein the incubating step is performed at room temperature.

### Claim 8 (depends on 1)

The method of claim 1, wherein the incubating step is performed for at least 30 minutes.

### Claim 9 (depends on 1)

The method of claim 1, wherein the heparin in the providing step is present in an amount of from 0.001 to 1 U/mL.

### Claim 10 (depends on 1)

The method of claim 1, wherein the heparin in the providing step is present in an amount of from 50 to 1000 U/mL.

### Claim 11 (depends on 1)

The method of claim 1, further comprising contacting the incubated sample with an internal standard prior to the chromatographically separating step.

### Claim 12 (depends on 11)

The method of claim 11, wherein the internal standard is a stable isotopically-labeled form of serotonin.

### Claim 13 (depends on 12)

The method of claim 12, wherein the stable isotopically-labeled form of serotonin comprises deuterium labeled serotonin, carbon-13 labeled serotonin, nitrogen-15 labeled serotonin, oxygen-18 labeled serotonin, or combinations thereof.

### Claim 14 (depends on 11)

The method of claim 11, wherein the internal standard is serotonin-d4.

### Claim 15 (depends on 1)

The method of claim 1, wherein the donor platelets in the providing step were incubated with serotonin prior to the providing step.

### Claim 16 (depends on 1)

The method of claim 1, wherein the donor platelets in the providing step were incubated with deuterium labeled serotonin, carbon-13 labeled serotonin, nitrogen-15 labeled serotonin, oxygen-18 labeled serotonin, or combinations thereof prior to the providing step.

### Claim 17 (depends on 1)

The method of claim 1, further comprising partially purifying the incubated sample prior to the chromatographically separating step.

### Claim 18 (depends on 17)

The method of claim 17, wherein the partially purifying step comprises centrifuging the incubated sample.

### Claim 19 (depends on 1)

The method of claim 1, wherein using liquid chromatography includes using analytical liquid chromatography.

### Claim 20 (depends on 19)

The method of claim 19, wherein using analytical liquid chromatography includes using a reverse phase column.

### Claim 21 (depends on 1)

The method of claim 1, wherein using liquid chromatography includes using at least one column.

### Claim 22 (depends on 1)

The method of claim 1, wherein using liquid chromatography includes using two or more liquid chromatography columns in parallel, where the two or more liquid chromatography columns are connected inline to a single mass spectrometer.

### Claim 23 (depends on 22)

The method of claim 22, wherein using two or more liquid chromatography columns in parallel includes introducing the incubated sample to the two or more liquid chromatography columns at staggered times.

### Claim 24 (depends on 1)

The method of claim 1, wherein the analyzing step includes ionizing serotonin using an ionization technique selected from the group consisting of: electrospray ionization, atmospheric pressure chemical ionization, and atmospheric pressure photoionization.

### Claim 25 (depends on 1)

The method of claim 1, wherein the analyzing step includes detecting serotonin using a quadrupole mass spectrometer.

### Claim 26 (depends on 25)

The method of claim 25, wherein the quadrupole mass spectrometer is a triple quadrupole mass spectrometer.

### Claim 27 (depends on 26)

The method of claim 26, wherein the analyzing step includes: detecting intact serotonin ion in the first quadrupole; fragmenting intact serotonin ion in the second quadrupole to yield one or more serotonin fragment ions; and detecting the one or more serotonin fragment ions in the third quadrupole.

### Claim 28 (depends on 1)

The method of claim 1, wherein the analyzing step comprises ionizing the chromatographically separated serotonin to produce one or more serotonin ions having a mass/charge ratio comprising at least one of a precursor ion of 160.1±0.5, or a product ion of 115.1±0.5, 132.1±0.5, 105.1±0.5, or 89.1±0.5.

### Claim 29

A method for determining the presence or amount of released serotonin in a sample, the method comprising:
providing a sample comprising a biological sample, heparin, and serotonin-incubated platelets;
incubating the sample for a period of time to release serotonin from the platelets;
chromatographically separating serotonin from other components in the incubated sample using liquid chromatography; and
analyzing the chromatographically separated serotonin by mass spectrometry to determine the presence or amount of released serotonin in the sample relative to the total amount of serotonin available within the donor platelets.

### Claim 30

A method for determining the presence or amount of released stable isotopically labeled serotonin in a sample, the method comprising:
providing a sample comprising a biological sample, heparin, and stable isotopically labeled serotonin-incubated platelets;
incubating the sample for a period of time to release stable isotopically labeled serotonin from the platelets;
chromatographically separating stable isotopically labeled serotonin from other components in the incubated sample using liquid chromatography; and
analyzing the chromatographically separated stable isotopically labeled serotonin by mass spectrometry to determine the presence or amount of released stable isotopically labeled serotonin in the sample relative to the total amount of isotopically labeled serotonin available within the donor platelets.

### Claim 31 (depends on 30)

The method of claim 30, wherein the stable isotopically labeled serotonin is deuterium labeled serotonin, carbon-13 labeled serotonin, nitrogen-15 labeled serotonin, oxygen-18 labeled serotonin, or combinations thereof prior to the providing step.

### Claim 32

A method of generating a report useful for diagnosing a disease or condition associated with abnormal platelet activation, the method comprising:
(a) providing a sample comprising a biological sample, donor platelets, and heparin;
(b) incubating the sample for a period of time to release serotonin from the donor platelets;
(c) chromatographically separating serotonin from other components in the incubated sample using liquid chromatography;
(d) analyzing the chromatographically separated serotonin by mass spectrometry to determine the amount of released serotonin in the sample relative to the total amount of serotonin available within the donor platelets; and
(e) generating a report that recites the percentage release of serotonin in the sample.

### Claim 33 (depends on 32)

The method of claim 32, wherein the disease or condition is heparin-induced thrombocytopenia.

### Claim 34

A system for determining the presence or amount of serotonin in a sample, the system comprising:
(a) a station for providing a sample comprising a biological sample, donor platelets, and heparin;
(b) a station for incubating the sample for a period of time to release serotonin from the donor platelets;
(c) a station for chromatographically separating serotonin from other components in the incubated sample using liquid chromatography; and
(d) a station for analyzing the chromatographically separated serotonin by mass spectrometry to determine the presence or amount of released serotonin in the sample relative to the total amount of serotonin available within the donor platelets.
